Attaining WHO Level 4 Could Unlock Zimbabwe's Access to US$3 Billion Regional Pharma Market

Harare, Zimbabwe – A World Health Organization (WHO) mission has been in Zimbabwe to conduct a comprehensive assessment of the Medicines Control Authority of Zimbabwe (MCAZ), with the potential to elevate the nation to the highest global regulatory standard for medicines. 

The formal benchmarking evaluation, that took place from 27 April to 1 May 2026, is examined whether MCAZ meets the rigorous criteria for WHO Maturity Level 4 (ML4), the pinnacle of regulatory excellence under the WHO Global Benchmarking Tool (GBT).

Zimbabwe achieved Maturity Level 3 (ML3) in 2024, becoming only the sixth country in Africa to do so. ML3 signifies that a national regulatory authority possesses a stable, well-functioning, and integrated system capable of effectively ensuring the safety, quality, and efficacy of medicines. 

ML4 represents a significant advancement, indicating a regulatory system operating at an advanced level of performance with a demonstrated commitment to continuous improvement, transparency, and data-driven decision-making.

The significance of achieving ML4 extends far beyond regulatory prestige. For a developing nation like Zimbabwe, this status would fundamentally transform the pharmaceutical landscape, impacting public health security, industrial development, and international trade. 

An ML4 rating signals to the global community that Zimbabwe's regulatory decisions are reliable, science-based, and consistent with the highest international standards.

The current assessment is being conducted against the backdrop of Zimbabwe's ambitious pharmaceutical localization strategy. The country aims to increase the market share of locally manufactured essential medicines from less than 30% to at least 60% by 2030. 

This industrial transformation requires a regulatory environment that can inspire confidence among investors, international partners, and consumers both domestically and regionally.

A successful ML4 designation would position Zimbabwe as a Center of Regulatory Excellence in Africa. This status would enable the country to potentially serve as a reference regulator for other African nations with less developed regulatory capacity. The authority's regulatory decisions could be adopted or relied upon by neighboring countries, significantly enhancing Zimbabwe's regional influence and leadership in pharmaceutical oversight.

From an economic perspective, ML4 status would be a powerful catalyst for the local pharmaceutical industry. Regulatory authorities that achieve ML3 or ML4 are eligible for inclusion among WHO-Listed Authorities, a designation that significantly simplifies the pathway for medicines manufactured in Zimbabwe to access regional and international markets. 

This would open doors to the broader Southern African Development Community (SADC) pharmaceutical market, estimated at over US$3 billion.

For local manufacturers, an ML4-rated regulator means that products approved for the domestic market would face reduced barriers to registration in other countries that recognize WHO-listed authority decisions. 

This accelerates market access, reduces duplication of regulatory work, and enhances the commercial viability of local production. The increased demand from export markets could drive greater investment in manufacturing capacity and technology transfer.

Public health outcomes would also benefit substantially from this advancement. An ML4 regulatory system demonstrates advanced pharmacovigilance capabilities, enabling more effective monitoring of medicine safety throughout the product lifecycle. 

This includes real-time surveillance of adverse drug reactions and the rapid detection and removal of substandard or falsified products from the supply chain.

The legal and institutional framework supporting MCAZ is being strengthened to meet the demands of ML4. Legislative amendments are being considered to expand the authority's mandate to cover medical devices, increase penalties for dealing in falsified medicines, and enhance pharmacovigilance tracking systems. 

These reforms align with international best practices and address vulnerabilities in the current regulatory landscape.

According to available inspection metrics, MCAZ conducted 47 inspections between February and August 2025, achieving an overall compliance rate of 89 percent at the time of final inspection reports. 

The authority has also been publishing Zimbabwe Public Assessment Reports (ZimPARs), enhancing transparency and public accountability in the regulatory process. These efforts demonstrate the authority's commitment to meeting the advanced standards required for ML4.

The WHO assessment mission is examining multiple dimensions of MCAZ operations, including technical interviews, field visits, and site inspections of vigilance systems. The outcome of this evaluation will determine whether Zimbabwe joins the elite group of nations with ML4 status. 

Given the country's reported achievement of 99.8 percent compliance with the GBT in internal assessments, anticipation is high for a positive outcome that would mark a historic milestone in Zimbabwe's journey toward pharmaceutical self-sufficiency and regulatory excellence.